Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

Investors on Monday stripped billions from CSL’s market capitalisation, triggered by news of the impairment against its unpopular Vifor renal therapy acquisition, and the prospect of revenue and ...

Biotechnology business CSL, which specialises in bloods, vaccines and plasma products, flagged a US$5 billion (AU$6.9 billion) write-down of its assets. The Melbourne-headquartered company also ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its flu vaccine mandate, dealing ‌another blow to the ...

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...